A case study: Neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation

General Hospital Psychiatry

Volumn 33, Issue 6, 2011, Pages 640.e1-640.e2

  Ochi, Shinichiro ^a   Kawasoe, Koichiro ^a   Abe, Masao ^a   Fukuhara, Ryuji ^a   Sonobe, Kantaro ^a   Kawabe, Kentaro ^a   Ueno, Shu ichi ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CYP2D6 variant; Neuroleptic malignant syndrome; Risperidone; Schizophrenia

Indexed keywords

CYTOCHROME P450 2D6; DANTROLENE; DIAZEPAM; HALOPERIDOL; QUETIAPINE; RISPERIDONE; SULPIRIDE;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; AUDITORY HALLUCINATION; CASE REPORT; CONSCIOUSNESS DISORDER; CYP2D6 GENE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAPHORESIS; DRUG DOSE INCREASE; FEMALE; FEVER; GENE; GENETIC VARIABILITY; HUMAN; MUSCLE HYPERTONIA; NEUROLEPTIC MALIGNANT SYNDROME; PATIENT COMPLIANCE; PERSECUTORY DELUSION; SCHIZOPHRENIA; SIDE EFFECT;

EID: 82855175289     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2011.03.003     Document Type: Article

References (12)

1. Kawanishi C. Pharmacogenetic aspects of neuroleptic malignant syndrome. Curr Pharmacogenomics 2006, 4:113-119.
2. Sim SC. Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available from: http://www.imm.ki.se/cypalleles/cyp2d6.htm.
3. Pope H.G., Keck P.E., McElroy S.L. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986, 143:1227-1233.
4. Callagha J.T., Bergstrom R.F., Ptak L.R., Beasley C.M. Olanzapine pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999, 37:177-193.
5. Bertilsson L., Dahl M.L., Dalen P., Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002, 53:111-122.
6. Scordo M.G., Spina E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 2002, 3:201-218.
7. de Leon J., Susce M.T., Pan R.M., Fairchild M., Koch W.H., et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005, 66:15-27.
8. Arranz M.J., Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use?. Schizophr Bull 2008, 34:1130-1144.
9. Ueno S., Otani K., Kaneko S., Koshiro K., Kondoh K., et al. Cytochrome P-450 2D6 gene polymorphism is not associated with neuroleptic malignant syndrome. Biol Psychiatry 1996, 40:72-74.
10. Iwahashi K., Yoshihara E., Nakamura K., Ameno K., Watanabe M., Tsuneoka Y., et al. CYP2D6 HhaI genotype and the neuroleptic malignant syndrome. Neuropsychobiology 1999, 39:33-37.
11. Kato D., Kawanishi C., Kishida I., Furuno T., Suzuki K., et al. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. Eur J Clin Pharmacol 2007, 63:991-996.
12. Sabbagh A., Darlu P. Data-mining methods as useful tools for predicting individual drug response: application to CYP2D6 Data. Hum Hered 2006, 62:119-134.